|
|
| |
--- HEADER PLACEHOLDER CONTENT SECTION --- |
|
|
|
|
|
|
 |
| Alhemo® is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A or B with or without factor VIII or IX inhibitors. It is not known if Alhemo® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age. |
|
|
|
|
| More than a pen— |
| your everyday bleed protectiona |
| Alhemo® is a prophylaxis treatment in a prefilled, subcutaneous pen to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia B with or without inhibitors or hemophilia A with or without inhibitors. It is not known if Alhemo® is safe and effective in people receiving ongoing immune tolerance induction or in children younger than 12 years of age. |
| aIt is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding. |
|
|
|
| Get to know the Alhemo® penb |
|
|
 |
| No |
| IV Infusions |
|
 |
| No |
| mixing |
|
 |
| No |
| vials |
|
 |
No refrigeration
requiredd |
(up to 4 weeks
after first use) |
|
|
| No |
| IV Infusions |
|
|
|
| No |
| mixing |
|
|
|
| No |
| vials |
|
|
|
| No refrigeration |
| requiredc |
(up to 4 weeks
after first use) |
|
|
bRead the Instructions for Use for information about how to prepare and inject Alhemo®, and how to properly throw away used pens and needles. Your healthcare provider should show you or your caregiver how to use Alhemo® before you use it for the first time.
cNeedles provided separately and may require a prescription in some states. A new needle is required for each injection.
dStore in refrigerator before first use. After first use, Alhemo® can be stored at room temperature below 86 °F (30 °C) or in a refrigerator at 36 °F to 46 °F (2 °C to 8 °C) for up to 4 weeks.
|
| IV=intravenous. |
|
| 98% (78 people) rated the pen easy to use |
| 97% (78 people) rated the pen easy to learn to use |
| 99% (76 people) rated the pen easy to store |
| Easy=easy or very easy. |
|
|
| Study design: The study included 80 people with hemophilia A or B, with or without inhibitors and their caregivers. It aimed to assess how the Alhemo® pen-injector is easy to learn how to use and easy to use. After training, participants prepared and performed a single injection on an injection pad or dummy and training time, preparation, injections, and number of complete injections were measured. Participants rated the pen's ease of use on a scale of very difficult, difficult, neither difficult nor easy, easy, very easy. Limitations include different experiences with real at-home use and rating based on a 1 practice injection. |
|
| Keep scrolling to learn more about Alhemo® |
 |
|
| Important Safety Information for Alhemo® |
| What is the most important information I should know about Alhemo®? |
| |
• |
It is important to follow the daily dosing schedule of Alhemo® to stay protected against bleeding. This is especially important during the first 4 weeks of treatment to make sure a correct maintenance dose is established. Use Alhemo® exactly as prescribed by your healthcare provider (HCP). Do not stop using Alhemo® without talking to your HCP. If you miss doses or stop using Alhemo®, you may no longer be protected against bleeding |
| |
• |
Your HCP may prescribe factor VIII, factor IX, or bypassing agents during treatment with Alhemo®. Carefully follow your HCP’s instructions regarding when to use on-demand factor VIII, factor IX, or bypassing agents and the recommended dose and schedule for breakthrough bleeds |
|
| Please click here or scroll below for additional Important Safety Information. |
|
|
|
|
| The power to choose your path |
| “I like the once-daily dosing because of the small needle and a low dosage volume.” |
| Royal lives with hemophilia B with inhibitors, uses Alhemo®, and is an employee of Novo Nordisk. |
|
|
|
| |
|
| Living with hemophilia B with inhibitors, Royal has an inspiring story worth hearing. Learn about his experience with everyday treatment that fits his needs. |
|
|
|
 |
| Stay in the know |
| Be the first to get important updates about Alhemo®, including patient support programs, insurance information through NovoCare®, and more. |
|
|
|
 |
| Get connected with your Novo Nordisk Rare Blood Community Liaison (RBCL) |
| Life with a bleeding disorder can bring challenges. Our RBCLs are experienced and ready to provide you with one-on-one support, including: |
 |
Information about Alhemo® |
|
Bleeding disorder & lifestyle education |
|
Updates on local events |
|
Tools to help you manage your bleeding disorder |
|
|
|
|
|
| What is Alhemo® |
| Alhemo® (concizumab-mtci) injection 60 mg, 150 mg, or 300 mg is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A or B with or without factor VIII or IX inhibitors. |
| |
• |
It is not known if Alhemo® is safe and effective in people receiving ongoing immune tolerance induction (ITI) or in children younger than 12 years of age |
|
| Important Safety Information (cont’d) |
| Do not use Alhemo® if you are allergic to concizumab-mtci or any of the ingredients in Alhemo®. |
| Before using Alhemo®, tell your HCP about all of your medical conditions, including if you: |
| |
• |
Have a planned surgery. Talk to your HCP about when to stop using Alhemo® and when to start it again if you have a planned surgery |
| |
• |
Are pregnant, breastfeeding, or plan to become pregnant or breastfeed. It is not known if Alhemo® may harm your unborn baby or if Alhemo® passes into your breast milk |
|
| |
| |
◦ |
Your HCP may do a pregnancy test before you start treatment with Alhemo®. |
| |
◦ |
Females who are able to become pregnant, talk to your HCP about using effective birth control (contraception) methods during treatment with Alhemo® and for 7 weeks after ending treatment |
|
|
| Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and supplements. |
| What are the possible side effects of Alhemo®? |
| Alhemo® may cause serious side effects, including: |
| |
• |
Blood clots (thromboembolic events). Alhemo® may cause blood clots to form in blood vessels, such as in your arms, legs, heart, lung, brain, eyes, kidneys, or stomach. You may be at risk for getting blood clots if you use high or frequent doses of factor products or bypassing agents to treat breakthrough bleeds, or if you have certain conditions. Get medical help right away if you have any signs and symptoms of blood clots, including: swelling, warmth, pain, or redness of the skin; headache; trouble speaking or moving; eye pain or swelling; sudden pain in your stomach or lower back area; feeling short of breath or severe chest pain; confusion; numbness in your face; and problems with your vision |
| |
• |
Allergic reactions. Alhemo® can cause allergic reactions, including redness of the skin, rash, hives, itching, and stomach-area (abdominal) pain. Stop using Alhemo® and get emergency medical help right away if you develop any signs or symptoms of a severe allergic reaction, including: itching on large areas of skin; trouble swallowing; wheezing; pale and cold skin; dizziness due to low blood pressure; redness or swelling of lips, tongue, face, or hands; shortness of breath; tightness of the chest; and fast heartbeat |
|
| The most common side effects of Alhemo® include: bruising, redness, bleeding, itching, rash or lump at the injection site, headache, and hives. These are not all the possible side effects of Alhemo®. Call your doctor for medical advice about side effects. |
| Please see Prescribing Information and Medication Guide for Alhemo®. |
| Alhemo® is a prescription medication. |
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. |
|
|
| Please do not respond to this email. If you would like to contact us, please click here or call 1‑877‑744‑2579. |
|
Alhemo® is a registered trademark of Novo Nordisk Health Care AG
NovoCare® and NovoFine® are registered trademarks of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2025 Novo Nordisk All rights reserved. US25AHM00177 September 2025 |
 |
|
| --- FOOTER PLACEHOLDER CONTENT SECTION --- |
|
|
|
